Search

Your search keyword '"Enever, Yvanne"' showing total 10 results

Search Constraints

Start Over You searched for: Author "Enever, Yvanne" Remove constraint Author: "Enever, Yvanne"
10 results on '"Enever, Yvanne"'

Search Results

1. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

2. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

3. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

4. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

5. From O'Shaughnessy to opportunity: innovating Hepatology Trials in the UK.

6. Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]

7. This study is looking at a potential new treatment, secukinumab for patients diagnosed with non-ocular Behçet's Syndrome. Phase II wants to evaluate how safe and how effective secukinumab might be. Patients will be assigned to either the study drug (secukinumab) or placebo arm for 16 weeks, followed by 36 weeks of treatment for both groups. Double blind trial means that neither the patient nor the study team will be able to tell which arm the patient is allocated to.

8. Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2

9. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Catalog

Books, media, physical & digital resources